CA2955495C - High dosage strength tablets of rucaparib - Google Patents

High dosage strength tablets of rucaparib Download PDF

Info

Publication number
CA2955495C
CA2955495C CA2955495A CA2955495A CA2955495C CA 2955495 C CA2955495 C CA 2955495C CA 2955495 A CA2955495 A CA 2955495A CA 2955495 A CA2955495 A CA 2955495A CA 2955495 C CA2955495 C CA 2955495C
Authority
CA
Canada
Prior art keywords
tablet
rucaparib
tablet according
active pharmaceutical
pharmaceutical ingredient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2955495A
Other languages
English (en)
French (fr)
Other versions
CA2955495A1 (en
Inventor
Jeffrey Etter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharma and Schweiz GmbH
Original Assignee
Pharma and Schweiz GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma and Schweiz GmbH filed Critical Pharma and Schweiz GmbH
Publication of CA2955495A1 publication Critical patent/CA2955495A1/en
Application granted granted Critical
Publication of CA2955495C publication Critical patent/CA2955495C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2955495A 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib Active CA2955495C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462040849P 2014-08-22 2014-08-22
US62/040,849 2014-08-22
US201562101739P 2015-01-09 2015-01-09
US62/101,739 2015-01-09
PCT/US2015/045522 WO2016028689A1 (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Publications (2)

Publication Number Publication Date
CA2955495A1 CA2955495A1 (en) 2016-02-25
CA2955495C true CA2955495C (en) 2023-09-19

Family

ID=55347324

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2955495A Active CA2955495C (en) 2014-08-22 2015-08-17 High dosage strength tablets of rucaparib

Country Status (19)

Country Link
US (3) US9987285B2 (enExample)
EP (1) EP3182975B1 (enExample)
JP (3) JP6574477B2 (enExample)
KR (2) KR102803917B1 (enExample)
CN (2) CN113209033A (enExample)
AU (2) AU2015305696B2 (enExample)
BR (1) BR112017000865A2 (enExample)
CA (1) CA2955495C (enExample)
DK (1) DK3182975T3 (enExample)
FI (1) FI3182975T3 (enExample)
IL (1) IL249946B (enExample)
LT (1) LT3182975T (enExample)
MX (1) MX367260B (enExample)
NZ (1) NZ728392A (enExample)
PT (1) PT3182975T (enExample)
RS (1) RS67356B1 (enExample)
RU (1) RU2705156C2 (enExample)
SG (1) SG11201700265VA (enExample)
WO (1) WO2016028689A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230107902A (ko) 2014-02-05 2023-07-18 머크 샤프 앤드 돔 엘엘씨 Cgrp-활성 화합물에 대한 정제 제제
US12168004B2 (en) 2014-02-05 2024-12-17 Merck Sharp & Dohme Llc Treatment of migraine
RS67356B1 (sr) * 2014-08-22 2025-11-28 Pharma& Schweiz Gmbh Tablete rukapariba visoke doze
CN106008530B (zh) * 2016-07-24 2018-06-26 石家庄久正生物科技有限公司 一种抗卵巢癌药物Rucaparib关键中间体的制备方法
CN108201534A (zh) * 2016-12-16 2018-06-26 苏州苏融生物医药有限公司 一种瑞卡帕布口服缓控释药物组合物及其用途
US10875870B2 (en) 2017-01-24 2020-12-29 Assia Chemical Industries Ltd. Solid state forms of rucaparib and of rucaparib salts
MX2019011496A (es) 2017-03-27 2020-01-23 Tesaro Inc Composiciones de niraparib.
BR112020006039A2 (pt) * 2017-09-26 2020-10-06 Tesaro, Inc. formulações de niraparibe
WO2019130229A1 (en) 2017-12-28 2019-07-04 Mylan Laboratories Ltd Methods and intermediates for preparing rucaparib
US10933069B2 (en) 2018-01-05 2021-03-02 Cybrexa 1, Inc. Compounds, compositions, and methods for treatment of diseases involving acidic or hypoxic diseased tissues
US12383545B1 (en) 2018-06-08 2025-08-12 Allergan Pharmaceuticals International Limited Treatment of migraine
CN109111454A (zh) * 2018-08-01 2019-01-01 宁波金未生物科技有限公司 一种瑞卡帕布s-樟脑磺酸盐
CN108853030B (zh) * 2018-09-26 2021-10-01 上海朝晖药业有限公司 一种治疗恶性肿瘤的药物制剂及其制备方法
WO2020113500A1 (zh) * 2018-12-06 2020-06-11 上海诚妙医药科技有限公司 芦卡帕利樟脑磺酸盐的新晶型和制备方法及其用途
PH12022550037A1 (en) 2019-07-10 2023-04-12 Cybrexa 3 Inc Peptide conjugates of microtubule-targeting agents as therapeutics
EP3997093A1 (en) 2019-07-10 2022-05-18 Cybrexa 2, Inc. Peptide conjugates of cytotoxins as therapeutics
ES3014370T3 (en) 2020-04-28 2025-04-22 Rhizen Pharmaceuticals Ag Novel compounds useful as poly(adp-ribose) polymerase (parp) inhibitors
EP4182318B1 (en) 2020-07-14 2025-08-27 Assia Chemical Industries Ltd. Solid state forms of rucaparib salts
AU2021319090A1 (en) 2020-07-29 2023-03-02 Allergan Pharmaceuticals International Limited Treatment of migraine
WO2022090938A1 (en) 2020-10-31 2022-05-05 Rhizen Pharmaceuticals Ag Phthalazinone derivatives useful as parp inhibitors
WO2022140537A1 (en) 2020-12-22 2022-06-30 Allergan Pharmaceuticals International Limited Treatment of migraine
AU2022255809A1 (en) 2021-04-08 2023-10-26 Incozen Therapeutics Pvt. Ltd. Inhibitors of poly(adp-ribose) polymerase
JP2024533756A (ja) 2021-09-27 2024-09-12 アラガン ファーマスーティカルズ インターナショナル リミテッド アトゲパントを含む片頭痛の併用療法
JP2024543323A (ja) * 2021-11-10 2024-11-21 クリチテック，インコーポレイテッド ルカパリブ粒子およびその使用
EP4463232A1 (en) 2022-01-11 2024-11-20 Assia Chemical Industries Ltd. Solid state forms of rucaparib tosylate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL210415B1 (pl) 1999-01-11 2012-01-31 Agouron Pharma Pochodne indolu, środek farmaceutyczny i zastosowanie pochodnych indolu
EP1611137A1 (en) 2003-03-31 2006-01-04 Pfizer Inc. Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
ATE454893T1 (de) 2003-07-25 2010-01-15 Cancer Rec Tech Ltd Tricyclische parp-hemmer
MX2007003311A (es) 2004-09-22 2007-05-16 Pfizer Procedimiento para preparar inhibidores de poli (adp-ribosa) polimerasas.
JP2008513435A (ja) 2004-09-22 2008-05-01 ファイザー・インク ポリ（ａｄｐ−リボース）ポリメラーゼ阻害剤を含む治療用組成物
MX2007002461A (es) 2004-09-22 2008-03-13 Pfizer Formas polimorficas y amorfas de la sal fosfato de 8-fluoro-2-{4-[metilamino)metil]fenil}-1, 3, 4, 5-tetrahidro-6h-azepino [5, 4, 3-cd]indol-6-ona.
AU2009235426A1 (en) * 2008-04-09 2009-10-15 Lek Pharmaceuticals D.D. Granulation of active pharmaceutical ingredients
CA3024216C (en) * 2010-02-12 2021-03-30 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
ES2654670T3 (es) 2012-04-05 2018-02-14 Vertex Pharmaceuticals Incorporated Compuestos útiles como inhibidores de la cinasa ATR y terapias de combinación de los mismos
RS67356B1 (sr) * 2014-08-22 2025-11-28 Pharma& Schweiz Gmbh Tablete rukapariba visoke doze

Also Published As

Publication number Publication date
AU2015305696A1 (en) 2017-02-02
RU2705156C2 (ru) 2019-11-05
NZ728392A (en) 2023-06-30
JP2017525712A (ja) 2017-09-07
US20160051561A1 (en) 2016-02-25
AU2019272064B2 (en) 2021-11-18
SG11201700265VA (en) 2017-02-27
JP6797980B2 (ja) 2020-12-09
AU2015305696B2 (en) 2019-08-29
KR20230097211A (ko) 2023-06-30
EP3182975A1 (en) 2017-06-28
BR112017000865A2 (pt) 2017-12-05
RS67356B1 (sr) 2025-11-28
AU2019272064A1 (en) 2019-12-19
EP3182975A4 (en) 2018-04-18
RU2017109139A3 (enExample) 2019-03-06
KR20170043597A (ko) 2017-04-21
CA2955495A1 (en) 2016-02-25
DK3182975T3 (da) 2025-10-20
IL249946B (en) 2020-05-31
IL249946A0 (en) 2017-03-30
MX367260B (es) 2019-08-12
WO2016028689A1 (en) 2016-02-25
US20190099430A1 (en) 2019-04-04
JP2021038242A (ja) 2021-03-11
LT3182975T (lt) 2025-11-25
EP3182975B1 (en) 2025-10-01
FI3182975T3 (fi) 2025-11-13
MX2017001540A (es) 2017-05-11
JP7127101B2 (ja) 2022-08-29
JP2020002149A (ja) 2020-01-09
JP6574477B2 (ja) 2019-09-11
CN106794185A (zh) 2017-05-31
CN113209033A (zh) 2021-08-06
KR102803917B1 (ko) 2025-05-07
US20180200260A1 (en) 2018-07-19
US9987285B2 (en) 2018-06-05
US10130636B2 (en) 2018-11-20
PT3182975T (pt) 2025-10-28
RU2017109139A (ru) 2018-09-24

Similar Documents

Publication Publication Date Title
AU2019272064B2 (en) High dosage strength tablets of rucaparib
EP3606511B1 (en) Pharmaceutical composition comprising lenvatinib mesylate
EP3860606B1 (en) Pharmaceutical composition comprising lenvatinib esylate or tosylate
US20080118564A1 (en) Pharmaceutical Composition Containing Candesartan Cilexetil as Lipophilic Crystalline Substance
EP2340834A1 (en) Enhanced Solubility of Ziprasidone
EP3184103A1 (en) Pharmaceutical composition comprising atorvastatin or a salt thereof
US20090215756A1 (en) Formulations containing losartan and/or its salts
HK1232807B (en) High dosage strength tablets of rucaparib
HK1232807A1 (en) High dosage strength tablets of rucaparib
EP3784218A1 (en) Tablet compositions comprising abiraterone acetate
WO2025018959A1 (en) Film coated tablets of brivaracetam
EP4491177A1 (en) Film coated tablets of brivaracetam
EP4401708A1 (en) Pharmaceutical composition of bempedoic acid
WO2025018960A1 (en) A film coated tablet of brivaracetam
WO2016139681A2 (en) Pharmaceutical composition of tizanidine and process for preparing the same
EP4527378A1 (en) A film coated tablet of brivaracetam
EP3272348A1 (en) Pharmaceutical composition comprising idelalisib

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200813

EEER Examination request

Effective date: 20200813

EEER Examination request

Effective date: 20200813

EEER Examination request

Effective date: 20200813

EEER Examination request

Effective date: 20200813

EEER Examination request

Effective date: 20200813

EEER Examination request

Effective date: 20200813

EEER Examination request

Effective date: 20200813

EEER Examination request

Effective date: 20200813